Podcasts about bcma

  • 94PODCASTS
  • 592EPISODES
  • 38mAVG DURATION
  • 1EPISODE EVERY OTHER WEEK
  • Jun 10, 2025LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about bcma

Latest podcast episodes about bcma

The Musicians Mentor
Episode 74 - Twinnie

The Musicians Mentor

Play Episode Listen Later Jun 10, 2025 50:12


In todays episode of the podcast, I talk to Nashville based (but English born), Country-Pop singer/songwriter and actress - Twinnie Lee Moore. Known professionally as - 'Twinnie'.Originally from York, England - Twinnie started down the show business path at a young age and has always been involved in entertainment in some shape or form. As an actress she has won a BCMA best newcomer award, appeared in British television staples like 'Hollyoaks and Emmerdale and has even acted alongside A-Listers like Glenn Close and Christian Slater. Her singer/artist career is equally impressive and in this interview we explore more of that side as we talk about her first two solo records, general music life, writing credits with artists like Bryan Adams and Kylie Minogue (among others), relocating state side and performances at iconic music venues like the Grand Ole Opry and the Country Music Hall Of Fame.For more on Twinnie please visit www.twinnieofficial.com and make sure you follow her across all her socials.For more on Travis Marc or the Musicians Mentor, please visit - www.musicians-mentor.comFor our partnership with our friends over at Soundbrenner, please visit - ⁠⁠⁠⁠⁠⁠⁠⁠https://www.soundbrenner.com/pages/affiliate-travis-marc⁠

Blood Podcast
Single cell multi-omic analysis of leukemia stem cells, cyclophosphamide for non-immune effector cell-associated neurotoxicity, and glycosylation as a mediator of von Willebrand factor clearance

Blood Podcast

Play Episode Listen Later Jun 5, 2025 16:06


In this week's episode, we'll learn more about the identification and characterization of stem cell-like leukemia blasts using single cell multi-omics, cyclophosphamide as a treatment for non-immune effector cell-associated neurotoxicity in patients treated with B-cell maturation antigen, or BCMA, targeted CAR T-cell therapies, and how differences in glycosylation affect the clearance of human plasma-derived and recombinant von Willebrand factor concentrates.Featured Articles:Single-cell panleukemia signatures of HSPC-like blasts predict drug response and clinical outcomeCyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatmentEnhanced α2-3–linked sialylation determines the extended half-life of CHO-rVWF

ASCO Daily News
Day 5: Top Takeaways From ASCO25

ASCO Daily News

Play Episode Listen Later Jun 3, 2025 9:52


Dr. John Sweetenham shares highlights from Day 5 of the 2025 ASCO Annual Meeting, including data from large trials in advanced malignant melanoma and mCSPC plus a new approach to first-line treatment for patients with multiple myeloma who are not transplant eligible. Transcript Hello, I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast, with my takeaways on selected abstracts from Day 5 of the 2025 ASCO Annual Meeting. My disclosures are available in the transcript of this episode. The selected abstracts from this final day of ASCO25 include important new data from large, randomized trials in patients with advanced malignant melanoma and patients with metastatic castration-sensitive prostate cancer, as well as a new approach to the first-line treatment of patients with multiple myeloma who are not transplant eligible.  Starting with LBA9500, this study was conducted in patients with completely resected stage III or IV malignant melanoma and compared the combination of relatlimab plus nivolumab versus nivolumab alone in this population. The study, named the RELATIVITY-098 trial, was presented by Dr. Georgina Long from the University of Sydney, Australia. In her introduction to the study, Dr. Long explained that the current standard of care for adjuvant therapy of resected stage III/IV melanoma is with PD-1 monotherapy with nivolumab, but that about 50% of patients will suffer from a subsequent relapse. In the first-line setting in patients with advanced or unresectable melanoma, the combination of nivolumab with the LAG-3 inhibitor, relatlimab, has been previously shown to improve progression-free survival in the RELATIVITY-047 trial. The current study evaluated this same combination in the adjuvant setting. More than 1,000 patients from 24 countries were randomized to receive either nivolumab alone (546 patients) or the combination of nivolumab with relatlimab (547 patients). Both treatments were given for a maximum of 1 year or until progression of disease, unacceptable toxicity, withdrawal, or death. Various biomarker studies were also undertaken including LAG-3 and PD-1 expression on CD8-positive T cells. The primary endpoint of the study was relapse-free survival, and Dr. Long reported that this was the same in both arms of the study. For example, at 24 months, the relapse-free survival was 64% in the monotherapy arm compared with 62% in the combination arm. The hazard ratio was 1.01 and the P value was 0.928. Metastasis-free survival was also identical in both arms. No benefit was observed for the combination in any of the prespecified subgroups. No new toxicity signals emerged compared with the RELATIVITY-047 trial. Interestingly, the baseline surface expression of LAG-3 and co-expression of LAG-3 and PD-1 on CD8 T cells in the 098 adjuvant trial were lower than in the 047 advanced disease trial, perhaps explaining why the combination did not confer benefit over nivo alone in the adjuvant setting. This is an important result, demonstrating that results from one clinical setting cannot always be extrapolated to another. Although the combination has gained some use in the adjuvant setting, this study clearly demonstrates that more drug in this situation is no better and that monotherapy remains the current standard of care. Results from the AMPLITUDE trial for patients with metastatic castration-sensitive prostate cancer with alterations in homologous recombination repair (HRR) genes, in LBA5006, were presented today by Dr. Gerhardt Attard from University College London, UK. This international, multicenter study evaluated the combination of the selective PARP inhibitor, niraparib, in combination with abiraterone acetate and prednisone. The same combination has been previously shown to improve outcomes in castration-resistant metastatic prostate cancer harboring BRCA mutations in the MAGNITUDE study. The current trial included patients with castration-sensitive disease with HRR mutations including BRCA1/2. Six hundred and ninety-six patients were randomized between niraparib, abiraterone, and prednisone plus androgen deprivation therapy, or the same combination with placebo instead of niraparib. Permitted prior therapies included no more than 6 months of prior androgen deprivation therapy and the use of docetaxel, or prior palliative radiation therapy. The primary endpoint of the study was radiographic relapse-free survival. Dr. Attard reported that the risk for radiographic progression-free survival in the whole population was significantly reduced by 37% with niraparib and abiraterone acetate plus prednisone compared with the placebo arm. The radiographic progression-free survival risk reduction with niraparib in the prespecified BRCA1/2 subgroup was 48% and reached statistical significance compared with the placebo arm. The secondary endpoint of time to symptomatic progression was also improved with niraparib in the HRR population and the BRCA1/2 subgroup. There was a trend for overall survival favoring the niraparib combination. However, the overall survival data were immature at this first interim analysis and did not yet reach statistical significance. No new safety concerns emerged with the toxicity data consistent with the MAGNITUDE study. Less than 5% more of the patients on the experimental arm discontinued treatment in comparison to the control arm. The authors conclude that the AMPLITUDE study results support the use of niraparib, abiraterone, and prednisone as a new treatment option for patients with metastatic castration- sensitive prostate cancer and BRCA and homologous recombination repair gene alterations. The results certainly support this conclusion and are potentially practice-changing. Turning to hematologic malignancies, my final selection from today's presentations is Abstract 7504, presented by Dr. Hang Quach from St Vincent's Hospital, Melbourne, Australia, and describes a novel combination of elranatamab, daratumumab, and lenalidomide in patients with newly diagnosed multiple myeloma who are not transplant-eligible – the so-called MagnetisMM-6 trial part 1. Elranatamab is a novel bispecific T-cell engaging antibody directed against BCMA and CD3, which has previously been approved for certain patients with relapsed and refractory multiple myeloma. In the present study, this was combined with lenalidomide and daratumumab in newly diagnosed patients. The report today describes the dose-finding phase of this study, which was part 1, specifically addressing so-called dose level ‘G', comprising elranatamab 76mg subcutaneously every 4 weeks plus daratumumab 1800mg subcutaneously and lenalidomide 25mg given orally. Thirty-seven patients were entered at this dose level, of whom 32 were on treatment at the time of analysis. Early response data show an overall response rate of 97.3%. With median follow up of 7.9 months, the current CR rate is 27% with a VGPR rate of almost 68%. The most frequent toxicities were hematologic, with neutropenia observed in 75%. Some cytokine release syndrome was observed in about 60% of patients, but none was greater than grade 2. The authors conclude that this combination is active in untreated multiple myeloma, with manageable toxicity and evidence of responses which appear to deepen over time. The dose-finding component of this trial is continuing and will subsequently progress into a phase 3 trial based on the data from the current study. This will compare daratumumab plus lenalidomide with the same combination plus elranatamab in previously untreated patients. That concludes our special coverage from the 2025 ASCO Annual Meeting. Thanks for listening and we hope you have enjoyed listening to our top takeaways from ASCO25. If you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts. Disclaimer:  The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  Find out more about today's speaker:    Dr. John Sweetenham    Follow ASCO on social media:     @ASCO on Twitter    @ASCO on Bluesky    ASCO on Facebook    ASCO on LinkedIn     Disclosures:   Dr. John Sweetenham:    No relationships to disclose

BC Museums Association Podcast
MuseNews Ep. 51: Auctions, Awards, Announcements and Artistic Activism

BC Museums Association Podcast

Play Episode Listen Later May 30, 2025 23:58


Welcome to MuseNews, the BCMA's monthly museum sector news podcast. Each month, we recap some of the latest breaking news, happenings, and announcements from museums, galleries, and heritage organizations across BC and beyond. May 2025 Stories: As Hudson's Bay bids farewell, Indigenous groups call for transparency in artifact auction New Lytton Chinese History Museum rises from the ashes - Bella Coola News News Release: Vernon Public Art Gallery Announces $1,000,000 Donation Royal BC Museum launches music exhibit on change and resistance B.C. Aviation Museum is booming since the arrival of the Martin Mars Recognition Awards honour societies, organizations, Individuals If you have news you want to share on this program, please email us at bcma@museum.bc.ca BCMA thanks Digital Museums Canada for their sponsorship.

BC Museums Association Podcast
MuseNews Ep. 50: Heroes, Health and Histories.

BC Museums Association Podcast

Play Episode Listen Later May 2, 2025 26:27


Welcome to MuseNews, the BCMA's monthly museum sector news podcast. Each month we recap some of the latest breaking news, happenings, and announcements from museums, galleries, and heritage organizations across BC and beyond. April 2025 Stories: German artillery from First World War piece found buried at the PNE | Vancouver Sun New Terry Fox exhibit to open in the Canadian hero's hometown Reach Gallery Museum Abbotsford names new executive director Health-care providers to prescribe nature-inspired art for wellness at Vancouver Art Gallery Public access to Hudson Bay Company artifacts 'absolutely crucial,' Manitoba history prof says | CBC News Royal BC Museum sets a new course to share stories of Chinese migration - Greater Victoria News Museum of Vancouver's new CEO heralds conversations and community to engage visitors Britannia Mine Museum featured in latest episode of 'The Last of Us' If you have news you want to share on this program, please email us at bcma@museum.bc.ca

Black Clover Martial Arts Podcast
BCMA ep. 103 Let's talk about the UFC 314 Miami main card Volk vs Lopes. Is he the GOAT?

Black Clover Martial Arts Podcast

Play Episode Listen Later Apr 16, 2025 13:04


In this episode i'm going through the main card for UFC Miami. Volkanovoski beat the odds and father time to cap off one of the best UFC cards in a little while. this card really delivered. Lets talk about it. Enjoy,Kru LuckGym- www.LuckysMT.comPanteraBJJ -@PanteraJJ on Instagram

BC Museums Association Podcast
BCMA Podcast: Salmon and Ethical AI

BC Museums Association Podcast

Play Episode Listen Later Apr 14, 2025 42:42


Join our host Lorenda and Dr. Will Atlas, Salmon Watershed Scientist, for a conversation about SalmonVision. In partnership with Indigenous communities, SalmonVision harnesses the power of AI for salmon monitoring and conservation. Explore rivers, waterways, and an ethical side of AI.  Resources: SalmonVision Wild Salmon Center Pacific Salmon Foundation First Nations harness power of AI to monitor wild salmon stocks in B.C. | CBC News Using AI to track salmon could be a ‘game-changer' | The Narwhal Restoring Indigenous fish weirs in B.C. | The Narwhal Artificial Intelligence, Meet Indigenous Fishing Technology - Wild Salmon Center  

Black Clover Martial Arts Podcast
BCMA ep. 102 PFL kickboxing championship, Pride Muay Thai tourney, and I unbox my Anaconda fight wear stuff.

Black Clover Martial Arts Podcast

Play Episode Listen Later Apr 5, 2025 9:57


In this episode I recap Christophe Broccoli winning the PFL amateur Kickboxing World championship, then taking a couple of fighters to a Muay thai tournaments the following week as well as my unboxing of stuff sent to me by Anaconda fightwear. Hope you enjoy!Kru LuckGym - www.LuckysMT.com BJJ - @PanterraJJ

BC Museums Association Podcast
MuseNews Ep. 49 - Home Comings and Home Goings

BC Museums Association Podcast

Play Episode Listen Later Apr 2, 2025 19:13


Welcome to MuseNews, the BCMA's monthly museum sector news podcast. Each month we recap some of the latest breaking news, happenings, and announcements from museums, galleries, and heritage organizations across BC and beyond. March Stories:   West Van purchases Horseshoe Bay's Boathouse restaurant for new art museum  Summerland museum shares history Irish settler who helped develop the irrigation system - Penticton News - Castanet.net Kelowna Museum exhibit highlights Japanese Canadian dispossession The Whalers Washing House finally coming home - rabble.ca Possible 25 per cent tariff on books could kneecap local retailers  Horn heist: B.C. train museum gets railroaded by targeted thefts | CBC News Hundreds of items returned to First Nations in Vancouver Museum's ongoing repatriation process Outdoor exhibits reopening at Vancouver's Science World with gardening robot, more 

Black Clover Martial Arts Podcast
BCMA ep. 101 UFC 313, Liam Harrison and Are we still doing Martial arts?

Black Clover Martial Arts Podcast

Play Episode Listen Later Mar 12, 2025 14:27


Peace people! Welcome back to another episode of the BCMA podcast. In this episode I talk about the uneventful UFC 313 where Pereira lost his belt to Ankalaev. The Legend Liam Harrison retires. Lastly I have to rant on the tate of martial arts a bit after seeing the crowds reaction to the Tate brothers when they arrived at UFC 313. Hope you enjoy. Kru LuckGym - www.LuckysMT.comInstagram - @Luckysmuaythai. @Panterabjj

BC Museums Association Podcast
MuseNews Ep: 48: Paintings, Partnerships, and Pie

BC Museums Association Podcast

Play Episode Listen Later Mar 4, 2025 14:36


Welcome to MuseNews, the BCMA's monthly museum sector news podcast. Each month we recap some of the latest breaking news, happenings, and announcements from museums, galleries, and heritage organizations across BC and beyond. February Stories: Nanaimo Art Gallery's new exhibit explores unexpected outcomes Barkerville Heritage Trust secures 7 more years running the historic site Surrey artist takes aim at Trump, Musk, Bezos with provocative paintings Exploration Place, BC Bob launch partnership for fundraiser ‘This is reclamation'; Tk'emlúps Kúkpi7 Casimir discusses historical designation for former residential school site Toddler's $4k offer ends apple pie bid war in support of Salmon Arm heritage site

Discovering Forestry
Episode 199 - Tales of the Tree Industry with Chris Rippey - Part II

Discovering Forestry

Play Episode Listen Later Feb 24, 2025 25:18


Joe and Korey sit down with Chris Rippey, owner of Missouri Arborist Company, for the second and final part of this two part episode. In the second part Chris, a BCMA and RCA, shares some of his wildest stories from his career in the tree industry. If you would like to know more about Chris' company you can visit www.MissouriArborist.com for more information. Additionally if you or someone you know needs help with drugs or addition you can visit the following resources: https://www.samhsa.gov/find-help/helplines/national-helpline or https://www.usa.gov/substance-abuse  If you enjoyed the podcast please rate, review, subscribe and tell a fellow tree lover! Send your questions or topics you would like us to discuss to ⁠info@discoveringforestrypodcast.com⁠.Be sure to follow us on all your favorite social media platforms! Twitter/X: @DisForestryPod Instagram: @discovering_forestry Facebook: Discovering Forestry YouTube: @discoveringforestry6905 LinkedIn: Discovering Forestry PodcastMusic credit:⁠ Cool Tools Music Video - "Timber"⁠   ⁠Muzaproduction “Sport Rock Logo 1”⁠Hosted by: Joe Aiken & Korey LofyProduced by: Nico ManganielloArtwork by: Cara Markiewicz & Nico Manganiello

Research To Practice | Oncology Videos
Multiple Myeloma — An Interview with Dr Surbhi Sidana on Optimizing the Role of CAR T-Cell Therapy

Research To Practice | Oncology Videos

Play Episode Listen Later Feb 18, 2025 28:06


Featuring a slide presentation and related discussion from Dr Surbhi Sidana, including the following topics: Key clinical data of FDA-approved chimeric antigen receptor (CAR) T-cell therapies (0:00) Real-world evidence evaluating utility of CAR T-cell therapies in the clinic (8:08) Impact of prior BCMA-targeted treatment on CAR T-cell therapy efficacy (12:55) Investigational CAR T-cell therapies in clinical development (15:08) Incidence and management of toxicities associated with CAR T-cell therapy (18:21) CME information and select publications

Discovering Forestry
Episode 198 - Tales of the Tree Industry with Chris Rippey - Part I

Discovering Forestry

Play Episode Listen Later Feb 17, 2025 23:18


Joe and Korey sit down with Chris Rippey, owner of Missouri Arborist Company, for part one of a two part episode. Chris, a BCMA and RCA, shares some of his wildest stories from his career in the tree industry. Chris and the guys also take an in depth look at the tree care industry and where to find the monetary value as someone working in the industry. If you would like to know more about Chris' company you can visit www.MissouriArborist.com for more information. Additionally if you or someone you know needs help with drugs or addition you can visit the following resources: https://www.samhsa.gov/find-help/helplines/national-helpline or https://www.usa.gov/substance-abuse  If you enjoyed the podcast please rate, review, subscribe and tell a fellow tree lover! Send your questions or topics you would like us to discuss to ⁠info@discoveringforestrypodcast.com⁠.Be sure to follow us on all your favorite social media platforms! Twitter/X: @DisForestryPod Instagram: @discovering_forestry Facebook: Discovering Forestry YouTube: @discoveringforestry6905 LinkedIn: Discovering Forestry PodcastMusic credit:⁠ Cool Tools Music Video - "Timber"⁠   ⁠Muzaproduction “Sport Rock Logo 1”⁠Hosted by: Joe Aiken & Korey LofyProduced by: Nico ManganielloArtwork by: Cara Markiewicz & Nico Manganiello

CCO Oncology Podcast
Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting

CCO Oncology Podcast

Play Episode Listen Later Feb 10, 2025 20:01


In this episode, Shaji K. Kumar, MD, reviews key data on bispecific antibodies used to treat patients with relapsed/refractory multiple myeloma recently presented at the 2024 annual American Society of Hematology meeting, including:Early results with teclistamab combined with anti-CD38 therapyReal-world data with teclistamab including its use after other BCMA-targeted therapiesTalquetamab as bridging therapy to BCMA-targeted CAR T-cell therapyEvaluation of prophylactic tocilizumab for cytokine-release syndrome associated with bispecific antibody therapyPresenter:Shaji K. Kumar, MDMark and Judy Mullins Professor of Hematologic MalignanciesConsultant, Division of HematologyProfessor of MedicineChair, Myeloma, Amyloidosis and Dysproteinemia GroupResearch Chair, Division of HematologyAssociate Chair for Research, Department of MedicineMayo ClinicRochester, MinnesotaLink to full program:https://bit.ly/40bjFCZ

Black Clover Martial Arts Podcast
BCMA ep. 100 Big thank you to everyone and whose the number 2 in MMA Organizations?

Black Clover Martial Arts Podcast

Play Episode Listen Later Feb 1, 2025 19:24


In this episode I give a sincere thanks to evberyone that supported and we go down the rabbit hole to decide if there is a clear cut number two MMA promotion. Drop a comment below to let me know your thoughts. Hope you enjoy the show. Thank you all so much for listening along. Love you guys! Peace! Kru Luck www.LuckysMT.com @luckysmuaythai @Panterabjj

BC Museums Association Podcast
MuseNews Ep. 47: Destruction, Rebirth and Celebration

BC Museums Association Podcast

Play Episode Listen Later Jan 31, 2025 18:37


Welcome to MuseNews, the BCMA's monthly museum sector news podcast. Each month we recap some of the latest breaking news, happenings, and announcements from museums, galleries, and heritage organizations across BC and beyond. January Stories: Rebuilding Telegraph Cove: Community Mobilizes to Restore a Vital Economic Engine - West Coast NOW  Museum of Anthropology unveils first exhibit dedicated to the Nuxalk Nation | Georgia Straight Vancouver's source for arts, culture, and events Victoria museum display celebrates work of Japanese-Canadian photographer - Saanich News Northern B.C. museum honours pioneer female pilot from the early 1900s - Quesnel Cariboo Observer Museum of Northern BC commemorates 100 years with a reflective exhibit - Houston Today Unmasking heritage: the rise of women carvers on the North Coast - Houston Today Through sculpture, syilx Okanagan artist turns pictographs into towering 3D figures   If you have news you want to share on this program, please email us at bcma@museum.bc.ca

Black Clover Martial Arts Podcast
BCMA ep.99 UFC 311, ONE Championship, and Hot Take 2025

Black Clover Martial Arts Podcast

Play Episode Listen Later Jan 28, 2025 14:39


Welcome back! In this episode I talk about UFC 311 and how Merab used his cardio and his heart to defeat Umar Nurmagomedov. I touch on ONE Championship and the return of Marcelo Garcia. Finally I give my hot take for 2025. Hope you enjoy! Peace. Kru Luck Gym - www.LuckysMT.com Pantera Jiu Jitsu - @PanteraBJJ on Instagram

Oncology Brothers
Multiple Myeloma ASH 2024 Highlights with Dr. Robert Orlowski

Oncology Brothers

Play Episode Listen Later Jan 7, 2025 22:18


Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Robert Orlowski from MD Anderson Cancer Center to discuss groundbreaking studies presented at ASH 2024 focused on multiple myeloma. We dived into four key studies: 1.⁠ ⁠AQUILA: Explore the impact of early intervention using daratumumab for smoldering myeloma, which showed improved progression-free survival (PFS) and overall survival (OS). 2.⁠ ⁠Dara Based Quad Therapy: We discuss a meta-analysis reaffirming the use of quadruplet therapy with anti-CD38 for newly diagnosed multiple myeloma as the standard of care. 3.⁠ CARTITUDE-4: study highlights the benefits of CAR-T therapy in earlier lines of treatment for patients with lenalidomide-refractory disease. 4.⁠ ⁠Role of IVIG with BCMA Bispecific Antibodies: Discover how IVIG can reduce infection rates and improve overall survival when used alongside BCMA-targeted therapies. Tune in for an insightful discussion that will enhance your understanding of the latest advancements in multiple myeloma treatment. Don't forget to check out our other episodes on CLL, myeloma, and lymphoma from ASH 2024! Subscribe to the Oncology Brothers for more updates and expert insights in oncology! Website: http://www.oncbrothers.com/  X/Twitter: https://twitter.com/oncbrothers  Contact us at info@oncbrothers.com

Blood Podcast
Primary resistance to BCMA-targeted bispecifics in multiple myeloma, emapalumab therapy in hemophagocytic lymphohistiocytosis, and chemotherapy-induced pyroptosis as a mechanism of thrombus formation in patients with cancer

Blood Podcast

Play Episode Listen Later Dec 19, 2024 20:05


In this week's episode, we'll learn more about mechanisms of primary resistance to BCMA-targeted bispecific T-cell engagers in relapsed/refractory multiple myeloma, the effects of emapalumab therapy on outcomes in patients with pediatric hemophagocytic lymphohistiocytosis who receive stem cell transplants, and a cell death process that may help account for increased thromboembolic risk in patients receiving cancer chemotherapy.Featured Articles:Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myelomaEmapalumab therapy for hemophagocytic lymphohistiocytosis before reduced-intensity transplantation improves chimerismGSDME-mediated pyroptosis contributes to chemotherapy-induced platelet hyperactivity and thrombotic potential

Black Clover Martial Arts Podcast
BCMA ep. 98 Lets catch up.

Black Clover Martial Arts Podcast

Play Episode Listen Later Dec 6, 2024 9:54


In this short episode I catch you up on the long break and what we missed the last couple of weeks. Enjoy. Peace, Kru Luck www.LuckysMT.com @Luckysmuaythai --- Support this podcast: https://podcasters.spotify.com/pod/show/bcma/support

Blood Podcast
Clonal hematopoiesis in patients with telomere biology disorders, genomic alterations in extracutaneous juvenile xanthogranulomas, and the BCMA-CD3 bispecific antibody teclistamab in relapsed/refractory multiple myeloma

Blood Podcast

Play Episode Listen Later Dec 5, 2024 20:11


In this week's episode we'll learn more about how clonal hematopoiesis affects prognosis in patients with telomere biology disorders, consider recently uncovered molecular subtypes of extracutaneous juvenile xanthogranulomas, and discuss a clinical trial of the BCMA-CD3 bispecific antibody teclistamab in patients with relapsed/refractory multiple myeloma who have received previous BCMA-targeted therapy.Featured Articles:Clonal landscape and clinical outcomes of telomere biology disorders: somatic rescue and cancer mutationsRecurrent CLTC::SYK fusions and CSF1R mutations in juvenile xanthogranuloma of soft tissueEfficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Black Clover Martial Arts Podcast
BCMA ep. 97 My UFC 308 picks and recap of PFL. Ngannou and Cyborg make history.

Black Clover Martial Arts Podcast

Play Episode Listen Later Oct 25, 2024 13:40


In this episode I talk about the recent PFL event that saw a return of Francis Ngannou to the MMA stage as well as Cris Cyborg making big MMA history. I also give some picks for UFC 308 Holloway vs Topuria. Hope you enjoy. Kru Luck Gym - www.LuckysMT.com Instagram - @Luckysmuaythai @Carreromartialarts --- Support this podcast: https://podcasters.spotify.com/pod/show/bcma/support

CCO Oncology Podcast
Relapsed/Refractory Multiple Myeloma: Role and Safety of Bispecific Antibodies

CCO Oncology Podcast

Play Episode Listen Later Oct 22, 2024 20:40


In this episode, Caitlin Costello, MD, discusses important topics related to relapsed/refractory (R/R) multiple myeloma (MM), including:3 bispecific antibodies approved for the treatment of R/R MM that target BCMA or GPRC5DThe role of bispecific antibodies in R/R MMSafety considerations for patients while receiving a bispecific antibodyEmerging data and clinical trials with bispecific antibodiesKey clinical pearls for optimal use of bispecific antibodiesPresenter:Caitlin Costello, MDClinical Professor of MedicineDirector, Multiple Myeloma ProgramDivision of Blood and Marrow TransplantationMoores Cancer CenterUC San DiegoLa Jolla, CaliforniaLink to full program: https://bit.ly/40bjFCZ

Black Clover Martial Arts Podcast
BCMA ep. 96 Pereira vs Roundtree and PFL Ngannou vs Ferreira

Black Clover Martial Arts Podcast

Play Episode Listen Later Oct 12, 2024 15:32


In this episode I talk about what went down between Khalil Roundtree jr. and Alex Pereira. What did Alex do that changed the way thre fight was going? Also, a little bit about the upcoming PFL Pay-per-view featuring the return of Francis Ngannou. Hope you enjoy. Peace, Kru Luck Gym - www.LuckysMT.com Instagram - @Luckysmuaythai @Carreromartialarts --- Support this podcast: https://podcasters.spotify.com/pod/show/bcma/support

Black Clover Martial Arts Podcast
BCMA ep. 95 ONE Denver ans Ufc Noché O'Malley vs Dvaslishvili

Black Clover Martial Arts Podcast

Play Episode Listen Later Sep 19, 2024 13:08


In this episode I recap One Championship Denver Superlek vs Haggerty and I give my thoughts on UFC Noché at the Sphere in Vegas. Great fights for the last couple of weeks so heres my two cents. Enjoy, Kru Luck Gym - www.LuckysMT.com Insta - @Luckysmuaythai @Carreromartialarts --- Support this podcast: https://podcasters.spotify.com/pod/show/bcma/support

ASTCT Talks
Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

ASTCT Talks

Play Episode Listen Later Sep 3, 2024 18:21


In a special co-branded episode between Oncology On the Go and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program ASTCT Talks, Rahul Banerjee, MD, FACP, and Noopur Raje, MD, discussed the risk of secondary malignancies in patients with multiple myeloma who receive CAR T-cell therapy. Banerjee is an assistant professor in the Clinical Research Division of Fred Hutchinson Cancer Center and an assistant professor in the Division of Hematology and Oncology at the University of Washington. Raje is the director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center and a professor of medicine at Harvard Medical School. Banerjee and Raje spoke in the context of prior advisories from the FDA on the potential development of secondary T-cell malignancies in patients who receive CAR T-cell therapy for hematologic cancers. Specifically, the agency required a boxed warning for secondary T-cell malignancy risks for BCMA- or CD19-targeting therapies in April 2024.1 The conversation also touched upon reports of secondary malignancies in cases and trials such as CARTITUDE-1 (NCT04181827), in which second primary cancers were highlighted in 9 patients who received treatment with ciltacabtagene autoleucel (Carvykti).2 Considering these reports and warnings, Banerjee and Raje emphasized shared treatment decision-making with patients after assessing the risks and benefits of CAR T-cell therapy compared with other agents like bispecific antibodies. They also reviewed optimal strategies for monitoring and referring patients based on the incidence of certain toxicities. “[Treatment with] CAR T cells requires planning, and we need to have good control of the disease. We need to have 4 to 6 weeks of a lead time to get these effective treatments to our patients, so early referral is a good idea,” Raje said. “[For example], if you see chronic diarrhea in someone that is way out of the window of what you would expect, referring back to the CAR T-cell center is important so that we don't miss some of these toxicities.” References FDA requires boxed warning for T cell malignancies following treatment with BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies. News release. FDA. April 18, 2024. Accessed August 22, 2024. https://tinyurl.com/5n8pm5ca San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335-347. doi:10.1056/NEJMoa2303379

Oncology Peer Review On-The-Go
S1 Ep125: Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

Oncology Peer Review On-The-Go

Play Episode Listen Later Sep 2, 2024 18:21


In a special co-branded episode between Oncology On the Go and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program ASTCT Talks, Rahul Banerjee, MD, FACP, and Noopur Raje, MD, discussed the risk of secondary malignancies in patients with multiple myeloma who receive CAR T-cell therapy. Banerjee is an assistant professor in the Clinical Research Division of Fred Hutchinson Cancer Center and an assistant professor in the Division of Hematology and Oncology at the University of Washington. Raje is the director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center and a professor of medicine at Harvard Medical School. Banerjee and Raje spoke in the context of prior advisories from the FDA on the potential development of secondary T-cell malignancies in patients who receive CAR T-cell therapy for hematologic cancers. Specifically, the agency required a boxed warning for secondary T-cell malignancy risks for BCMA- or CD19-targeting therapies in April 2024.1 The conversation also touched upon reports of secondary malignancies in cases and trials such as CARTITUDE-1 (NCT04181827), in which second primary cancers were highlighted in 9 patients who received treatment with ciltacabtagene autoleucel (Carvykti).2  Considering these reports and warnings, Banerjee and Raje emphasized shared treatment decision-making with patients after assessing the risks and benefits of CAR T-cell therapy compared with other agents like bispecific antibodies. They also reviewed optimal strategies for monitoring and referring patients based on the incidence of certain toxicities. “[Treatment with] CAR T cells requires planning, and we need to have good control of the disease. We need to have 4 to 6 weeks of a lead time to get these effective treatments to our patients, so early referral is a good idea,” Raje said. “[For example], if you see chronic diarrhea in someone that is way out of the window of what you would expect, referring back to the CAR T-cell center is important so that we don't miss some of these toxicities.”  References 1. FDA requires boxed warning for T cell malignancies following treatment with BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies. News release. FDA. April 18, 2024. Accessed August 22, 2024. https://tinyurl.com/5n8pm5ca  2. San-Miguel J, Dhakal B, Yong K, et al. CIlta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335-347. doi:10.1056/NEJMoa2303379 

Black Clover Martial Arts Podcast
BCMA ep. 94 What happened to Izzy? CJI better than ADCC?

Black Clover Martial Arts Podcast

Play Episode Listen Later Sep 1, 2024 17:23


In this episode I rant about the things I thought went wrong for Israel Adesanya in his title fight with fellow African Dricus DuPlesis. I also go off about how good CJI was for BJJ and hwo Craig Jones is the face of Jiu Jitsu. Enjoy! Kru LuckGym - www.LuckysMT.com Insta - @Luckysmuaythai BJJ - @Carrerobjj --- Support this podcast: https://podcasters.spotify.com/pod/show/bcma/support

Black Clover Martial Arts Podcast
BCMA ep. 92 Diaz, Masvidal, Periera, and DDP vs Adesanya

Black Clover Martial Arts Podcast

Play Episode Listen Later Aug 11, 2024 14:18


In this episode I talk about the Nate Diaz victory over Jorge Masvidal as well as Periera saving the UFC again. DDP faced off against Israel Adesanya and it was intense! Peave and blessings, Kru Luck --- Support this podcast: https://podcasters.spotify.com/pod/show/bcma/support

Black Clover Martial Arts Podcast
BCMA ep. 93 Ufc Abu Dhabi Nurmagamedov vs Sandhagen, Crawford vs Medramov equals no Canelo?

Black Clover Martial Arts Podcast

Play Episode Listen Later Aug 11, 2024 19:35


In this episode I recap some of Ufc Abu Dhabi as well as the end for Tony Ferguson maybe? Terence Crawford vs Madrimov fight. Does his performance mean no Canelo fight?? Enjoy, Kru Luck --- Support this podcast: https://podcasters.spotify.com/pod/show/bcma/support

Discovering Forestry
Episode 174 - Talking TRAQ and Trees with Long Time BCMA and Friend, Ben Brusie

Discovering Forestry

Play Episode Listen Later Aug 5, 2024 29:22


Joe and Korey sit down with Ben Brusie, Arborist and Owner of Green Ridge Plant Care. Ben and the guys discuss his career and the importance of continuing to educate yourself as you move through your career. For more on Green Ridge Plant Care you can visit https://www.greenridgeplantcare.com/index.html If you enjoyed the podcast please rate, review, subscribe and tell a fellow tree lover! Send your questions or topics you would like us to discuss to ⁠info@discoveringforestrypodcast.com⁠. Be sure to follow us on all your favorite social media platforms! Twitter/X: @DisForestryPod Instagram: @discovering_forestry Facebook: Discovering Forestry YouTube: @discoveringforestry6905 LinkedIn: Discovering Forestry Podcast Music credit:⁠ Cool Tools Music Video - "Timber"⁠   ⁠Muzaproduction “Sport Rock Logo 1”⁠ Hosted by: Joe Aiken & Korey Lofy Produced by: Nico Manganiello Artwork by: Cara Markiewicz & Nico Manganiello --- Support this podcast: https://podcasters.spotify.com/pod/show/discoveringforestry/support

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Peter Voorhees, MD - Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 3, 2024 113:26


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRK865. CME/MOC/AAPA/IPCE credit will be available until July 1, 2025 .Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), and Sanofi.Disclosure information is available at the beginning of the video presentation.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Peter Voorhees, MD - Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 3, 2024 113:24


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRK865. CME/MOC/AAPA/IPCE credit will be available until July 1, 2025 .Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), and Sanofi.Disclosure information is available at the beginning of the video presentation.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Peter Voorhees, MD - Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 3, 2024 113:26


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRK865. CME/MOC/AAPA/IPCE credit will be available until July 1, 2025 .Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), and Sanofi.Disclosure information is available at the beginning of the video presentation.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Peter Voorhees, MD - Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 3, 2024 113:26


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRK865. CME/MOC/AAPA/IPCE credit will be available until July 1, 2025 .Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), and Sanofi.Disclosure information is available at the beginning of the video presentation.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Peter Voorhees, MD - Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 3, 2024 113:24


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRK865. CME/MOC/AAPA/IPCE credit will be available until July 1, 2025 .Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), and Sanofi.Disclosure information is available at the beginning of the video presentation.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Peter Voorhees, MD - Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 3, 2024 113:24


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRK865. CME/MOC/AAPA/IPCE credit will be available until July 1, 2025 .Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), and Sanofi.Disclosure information is available at the beginning of the video presentation.

Black Clover Martial Arts Podcast
BCMA ep. 91 Conor out Pereira in, Gervonta Davis, Silva vs Sonnen, and IS IZZY BACK?

Black Clover Martial Arts Podcast

Play Episode Listen Later Jun 19, 2024 19:10


In this episode I talk about the big UFC 303 shake up, with Poatan and Jiri for the save. Gervonta takes out Frank Martin with a big KO. Was Silva vs Sonnen a work? Finally, is Israsel Adesanya back against DuPlessis for the title in Perth? A lot of questions and I do my best to weed through it all. Hope you enjoy. Peace and blessings, Kru Luck www.LuckysMT.com @luckysmuaythai @Carrerobjj --- Support this podcast: https://podcasters.spotify.com/pod/show/bcma/support

Black Clover Martial Arts Podcast
BCMA ep.90 Victory for the team, Conor out?, Sonnen vs Silva etc

Black Clover Martial Arts Podcast

Play Episode Listen Later Jun 14, 2024 14:28


In this episode I rant on about so much happening in the fight world. Is Conor going to make the walk, Chael Sonnen finally gets a chance at redemption against Anderson Silva in the best way possible. Did Craig Jones just expose ADCC? so much happening. Hope you enjoy. Peace and Blessings Kru Luck Gym - www.LuckysMT.com @Luckysmuaythai BJJ - @Carrerobjj on Instagram --- Support this podcast: https://podcasters.spotify.com/pod/show/bcma/support

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Prof. Mohamad Mohty, MD, PhD / Caitlin Costello, MD - Five Steps for Integrating BCMA Bispecific Innovations: From Clinical Data to Clinical Practice in RRMM

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 11, 2024 33:20


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPD information, and to apply for credit, please visit us at PeerView.com/CAN865. CME/CPD credit will be available until 5 June 2025.Five Steps for Integrating BCMA Bispecific Innovations: From Clinical Data to Clinical Practice in RRMM In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Prof. Mohamad Mohty, MD, PhD / Caitlin Costello, MD - Five Steps for Integrating BCMA Bispecific Innovations: From Clinical Data to Clinical Practice in RRMM

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 11, 2024 33:36


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPD information, and to apply for credit, please visit us at PeerView.com/CAN865. CME/CPD credit will be available until 5 June 2025.Five Steps for Integrating BCMA Bispecific Innovations: From Clinical Data to Clinical Practice in RRMM In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Prof. Mohamad Mohty, MD, PhD / Caitlin Costello, MD - Five Steps for Integrating BCMA Bispecific Innovations: From Clinical Data to Clinical Practice in RRMM

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 11, 2024 33:20


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPD information, and to apply for credit, please visit us at PeerView.com/CAN865. CME/CPD credit will be available until 5 June 2025.Five Steps for Integrating BCMA Bispecific Innovations: From Clinical Data to Clinical Practice in RRMM In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Prof. Mohamad Mohty, MD, PhD / Caitlin Costello, MD - Five Steps for Integrating BCMA Bispecific Innovations: From Clinical Data to Clinical Practice in RRMM

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 11, 2024 33:20


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPD information, and to apply for credit, please visit us at PeerView.com/CAN865. CME/CPD credit will be available until 5 June 2025.Five Steps for Integrating BCMA Bispecific Innovations: From Clinical Data to Clinical Practice in RRMM In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Prof. Mohamad Mohty, MD, PhD / Caitlin Costello, MD - Five Steps for Integrating BCMA Bispecific Innovations: From Clinical Data to Clinical Practice in RRMM

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 11, 2024 33:36


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPD information, and to apply for credit, please visit us at PeerView.com/CAN865. CME/CPD credit will be available until 5 June 2025.Five Steps for Integrating BCMA Bispecific Innovations: From Clinical Data to Clinical Practice in RRMM In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

Black Clover Martial Arts Podcast
BCMA Ep. 89 I talk about Domestic Violence since the Puffy tape, Boxing is killing it right now.

Black Clover Martial Arts Podcast

Play Episode Listen Later May 26, 2024 12:30


BCMA Ep. 89 I talk about Domestic Violence since the Puffy tape, Boxing is killing it right now. Also, Anderson Silva's announcement and my thoughts on that. Hope you enjoy. Peace and Blessings Kru Luck Gym - www.LuckysMT.com Instagram - @Luckysmuythai Carrero Jiu Jitsu - @Carrerobjj --- Support this podcast: https://podcasters.spotify.com/pod/show/bcma/support

Research To Practice | Oncology Videos
Multiple Myeloma | Oncology Today with Dr Neil Love: Bispecific Antibodies in the Management of Multiple Myeloma (Companion Faculty Lecture)

Research To Practice | Oncology Videos

Play Episode Listen Later May 24, 2024 29:05


Featuring a slide presentation and related discussion from Dr Joshua Richter, including the following topics: Similarities and differences between the cellular targets and mechanisms of action of BCMA- and non-BCMA-directed bispecific antibodies for multiple myeloma (MM) (0:00) Antitumor activity observed with teclistamab and elranatamab for relapsed/refractory MM (3:46) Published findings with investigational anti-BCMA bispecific antibodies such as linvoseltamab and alnuctamab for pretreated MM (12:40) Efficacy and safety of approved and investigational non-BCMA-targeted bispecific antibodies in patients with heavily pretreated MM (16:26) Early data with bispecific antibodies in combination with other systemic therapies for MM (22:55) Spectrum, incidence, severity and timing of cytokine release syndrome, neurotoxicity and other adverse events with BCMA- and non-BCMA-targeted bispecific antibodies (26:39) CME information and select publications

Research To Practice | Oncology Videos
Multiple Myeloma | Oncology Today with Dr Neil Love: Bispecific Antibodies in the Management of Multiple Myeloma

Research To Practice | Oncology Videos

Play Episode Listen Later May 24, 2024 41:54


Featuring an interview with Dr Joshua Richter, including the following topics: Management of cytokine release syndrome after bispecific antibody therapy; importance of clinical trials in the multiple myeloma (MM) treatment paradigm (0:00) Similarities and differences between and efficacy and tolerability of BCMA- and non-BCMA-directed bispecific antibodies in the treatment of MM (7:18) Case: A woman in her mid 60s with penta-refractory MM who achieves complete remission with linvoseltamab on a clinical trial (12:53) Case: A woman in her early 60s with multiregimen-refractory MM who experiences pain and tumor flare during step-up dosing of teclistamab (22:40) Case: A man in his late 60s with relapsed/refractory MM who experiences disease relapse 18 months after chimeric antigen receptor T-cell therapy begins treatment with talquetamab (28:34) Racial and ethnic disparities in the treatment of MM (32:09) CME information and select publications

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO - Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 24, 2024 84:14


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at PeerView.com/FRR865. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 25, 2025.Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron Pharmaceuticals, Inc., and Sanofi.Disclosure information is available at the beginning of the video presentation.

BioCentury This Week
Ep. 222 - Crowley's Vision for BIO, Plus: MASH & CAR Ts

BioCentury This Week

Play Episode Listen Later Mar 18, 2024 20:48


Putting patients at center stage is at the core of John Crowley's vision for BIO as he begins his tenure leading the biotech trade group. On the latest BioCentury This Week podcast. Washington Editor Steve Usdin details Crowley's plans to revitalize BIO at a time when effective representation in Washington is more important than ever.BioCentury's editors also discuss FDA's landmark approval of Madrigal's liver disease drug and a decision by FDA's Oncologic Drugs Advisory Committee to support a pair of BCMA-directed CAR T cell therapies in earlier lines to treat multiple myeloma, and what's needed to help avoid deaths during the period while patient wait for the CAR T cells to be produced.